Osteoporosis is a common skeletal disease characterized by bone loss and subsequent
increased risk of fragility fractures. Recent advances in our mechanistic understanding of …

Human bones are in a continuous process of remodeling that ensures renovation and
maintenance of the skeletal mass. Bone remodeling has two phases that are normally …

Denosumab (anti-receptor activator of nuclear factorκB ligand [RANKL] antibody) is a novel
agent, a fully human monoclonal antibody that inhibits osteoclastic-medicated bone …

The cathepsin K (CatK) inhibitor odanacatib (ODN) is currently being developed for the
treatment of osteoporosis. In clinical trials, efficacy and resolution of effect of ODN treatment …

Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-
κB ligand (RANKL) which blocks its binding to RANK, inhibiting the development and activity …

Osteoporosis is a major public health care concern. Although often described as a disease
affecting postmenopausal women, researchers and clinicians have emphasized its …

Osteoporosis is a skeletal disease affecting millions of people worldwide in which a
decreased bone mass and a microarchitectural deterioration compromise bone strength …

Osteoporosis and several other bone disorders occur when there is an imbalance between
the resorption and formation components of bone remodeling activity. Therapies available …

Osteogenesis and bone remodeling are complex biological processes that are essential for
the formation of new bone tissue and its correct functioning. When the balance between …

To treat systemic bone loss as in osteoporosis and/or focal osteolysis as in rheumatoid
arthritis or periodontal disease, most approaches target the osteoclasts, the cells that resorb …